Novavax Inc. Stock Slides 4.0%, Underperforms Peers

Dow Jones2026/10/19 20:34

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

This article was automatically generated by Dow Jones using technology from Automated Insights.

Shares of Novavax Inc. slid 4.0% to $10.82 on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index rising 1.1% to 26,430.89 and the Dow Jones Industrial Average falling 0.1% to 51,966.03.

This was the stock's second consecutive day of losses.

Novavax Inc. closed 19.2% below its 52-week high of $13.39, which the company achieved on October 5th.

The stock underperformed when compared to some of its peers, as Johnson & Johnson fell 0.7% to $253.79, Pfizer Inc. fell 0.5% to $29.44, and Merck & Co. Inc. fell 1.59% to $143.63.

Trading volume totaled 6.2 million, compared to the 50-day average of 6.7 million.

Data source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

October 19, 2026 16:34 ET (20:34 GMT)

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

On Tuesday, Jay Clayton, Director of National Intelligence and Head of Artificial Intelligence Affairs in the United States, was asked during an interview when recommendations regarding AI would be made. He responded: "We will be rolling them out," but added that he could not commit to an exact date. On October 16, the newly established AI Special Task Force led by Jay Clayton under the Trump administration held its first meeting, with the task force officially operating for a term of 120 days.

华尔街见闻•2026/10/20 21:01